Resistant Hypertension Gets Personal: Aldosterone, Renin, and the Renewed Secondary Workup
Abstract
Purpose: Resistant hypertension remains a significant clinical challenge and is associated with a markedly increased risk of cardiovascular disease, chronic kidney disease progression, stroke, heart failure, and premature mortality. Despite the availability of multiple antihypertensive agents and evidence based treatment guidelines, a substantial proportion of patients fail to achieve adequate blood pressure control. Increasing evidence indicates that resistant hypertension should not be viewed merely as inadequate response to multiple medications but rather as a complex clinical syndrome with diverse underlying mechanisms, including medication nonadherence, secondary forms of hypertension, inappropriate pharmacologic regimens, and persistent volume overload. This review examines the evolving approach to the evaluation and management of resistant hypertension, with particular emphasis on aldosterone renin profiling, systematic screening for primary aldosteronism, comprehensive investigation for secondary causes of hypertension, optimization of pharmacologic therapy, and the integration of emerging treatment options into contemporary clinical practice.
Methodology: This review synthesizes current evidence from major international hypertension guidelines, consensus statements on primary aldosteronism, United States Food and Drug Administration labeling, official prescribing information, pivotal randomized controlled trials, systematic reviews, meta analyses, and other high quality clinical studies relevant to resistant hypertension. The literature was critically evaluated to examine contemporary diagnostic strategies, advances in endocrine evaluation, medication optimization, novel pharmacologic therapies, device based interventions, and evidence supporting individualized management. Particular attention was given to clinically applicable recommendations that assist physicians in differentiating true resistant hypertension from pseudo resistant hypertension while identifying patients most likely to benefit from targeted interventions.
Main Findings: Contemporary evidence supports a fundamental shift in the evaluation of resistant hypertension from a medication centered approach to a comprehensive diagnostic framework. Patients presenting with persistently elevated blood pressure despite multidrug therapy should undergo systematic confirmation of true treatment resistance before additional medications are prescribed. This process includes verification of accurate blood pressure measurement techniques, exclusion of the white coat effect through ambulatory or home blood pressure monitoring, assessment of medication adherence, evaluation of lifestyle factors, and identification of medications or substances that may contribute to elevated blood pressure.
Once pseudo resistance has been excluded, optimization of foundational antihypertensive therapy remains the cornerstone of management. Current recommendations emphasize the use of evidence based multidrug regimens, aggressive sodium restriction, appropriate diuretic selection according to kidney function, and correction of persistent volume overload. Particular emphasis is placed on screening for primary aldosteronism, now recognized as one of the most common and potentially treatable causes of resistant hypertension. Measurement and interpretation of the aldosterone renin ratio, followed by confirmatory testing and subtype classification when indicated, have become integral components of the diagnostic evaluation, enabling targeted treatment through mineralocorticoid receptor antagonists or adrenal intervention in appropriately selected patients.
Evaluation for additional secondary causes should proceed in a structured manner based on clinical presentation and individual risk factors. Conditions including chronic kidney disease, renovascular hypertension, obstructive sleep apnea, pheochromocytoma, Cushing syndrome, thyroid disorders, and medication induced hypertension should be considered as part of a comprehensive diagnostic assessment. Recognition and treatment of these underlying conditions frequently improve blood pressure control while reducing long term cardiovascular risk.
When blood pressure remains uncontrolled despite optimized conventional therapy, newer treatment modalities provide additional therapeutic options. Recently approved agents such as aprocitentan, a dual endothelin receptor antagonist, and investigational aldosterone synthase inhibitors such as baxdrostat have demonstrated clinically meaningful reductions in blood pressure among patients with resistant hypertension. In parallel, catheter based renal denervation has reemerged as a promising device based intervention for carefully selected individuals following improvements in procedural techniques and supportive clinical trial evidence. These advances broaden the therapeutic landscape and offer alternatives for patients with persistent hypertension despite comprehensive medical management.
However, current evidence indicates that these emerging therapies should complement rather than replace meticulous diagnostic evaluation and individualized treatment planning. Their demonstrated benefits have largely been confined to blood pressure reduction, while robust evidence confirming reductions in major cardiovascular outcomes such as myocardial infarction, stroke, heart failure, or cardiovascular mortality remains limited. Appropriate patient selection, careful monitoring for adverse effects, assessment of kidney function, potassium homeostasis, aldosterone renin physiology, coexisting medical conditions, reproductive considerations, and the capacity for long term follow up remain essential components of safe and effective therapy.
Overall, resistant hypertension should be recognized as a multifactorial clinical syndrome that requires systematic evaluation rather than progressive escalation of antihypertensive medications alone. Contemporary management integrates confirmation of true resistance, comprehensive investigation for secondary hypertension, optimization of lifestyle and pharmacologic therapy, endocrine evaluation, and selective incorporation of emerging pharmacologic and procedural interventions. This patient centered approach has the potential to improve blood pressure control, reduce treatment related complications, and enhance long term cardiovascular outcomes while promoting more precise and individualized care.
Keywords: resistant hypertension, primary aldosteronism, aldosterone-renin ratio, renin profiling, mineralocorticoid receptor antagonists, baxdrostat, aprocitentan, renal denervation
Introduction
Resistant hypertension is increasingly recognized as a diagnostic syndrome rather than a definitive therapeutic endpoint. Traditionally defined as blood pressure that remains above target despite the concurrent use of at least three antihypertensive medications of different classes, including an appropriate diuretic at optimal doses, resistant hypertension represents a complex clinical entity with diverse underlying causes. Similarly, patients whose blood pressure is controlled only through the use of four or more antihypertensive agents are also considered to have resistant hypertension. Importantly, persistent blood pressure elevation should not automatically be interpreted as true pharmacologic resistance. Instead, it should prompt a systematic evaluation to distinguish genuine treatment resistant hypertension from potentially reversible or modifiable factors that mimic resistance.
The first priority in evaluating apparent resistant hypertension is confirming the accuracy of the diagnosis. Improper blood pressure measurement techniques, use of incorrectly sized cuffs, inadequate patient preparation, and failure to obtain repeated standardized measurements can all lead to falsely elevated readings. In addition, white coat hypertension remains an important consideration, as some patients exhibit elevated blood pressure in the clinical setting despite well controlled ambulatory or home measurements. Confirmation with ambulatory blood pressure monitoring or validated home blood pressure monitoring is therefore essential before escalating pharmacologic therapy.
Medication adherence represents another critical determinant of apparent treatment resistance. Nonadherence is common among patients receiving complex antihypertensive regimens and may result from adverse effects, medication costs, polypharmacy, inadequate health literacy, or poor understanding of treatment goals. Studies suggest that a substantial proportion of patients initially classified as having resistant hypertension are ultimately found to have incomplete medication adherence. Careful medication reconciliation, patient centered communication, pharmacy refill review, and, when appropriate, objective adherence assessments can help identify this frequently overlooked contributor.
Lifestyle factors also play a major role in persistent hypertension. Excess dietary sodium intake remains one of the most important reversible causes of inadequate blood pressure control, particularly among salt sensitive individuals. Obesity, excessive alcohol consumption, physical inactivity, and untreated psychological stress may further contribute to sustained hypertension despite multidrug therapy. Optimizing lifestyle interventions should therefore remain an integral component of resistant hypertension management alongside pharmacologic treatment.
Clinicians should also carefully evaluate pharmacologic factors that may interfere with blood pressure control. Inadequate diuretic therapy, inappropriate medication combinations, and suboptimal dosing may all contribute to apparent resistance. In patients with reduced renal function or marked volume expansion, thiazide type diuretics may become less effective, making longer acting thiazide like agents or loop diuretics more appropriate depending on kidney function. Furthermore, numerous medications and substances may induce or exacerbate hypertension, including nonsteroidal anti inflammatory drugs, oral contraceptives, glucocorticoids, calcineurin inhibitors, erythropoiesis stimulating agents, sympathomimetic medications, certain antidepressants, and recreational substances. Identifying and modifying these contributing factors may remarkably improve blood pressure control.
Secondary hypertension is particularly prevalent among patients with resistant hypertension and should be actively investigated. Chronic kidney disease is both a cause and consequence of poorly controlled hypertension and frequently contributes to treatment resistance through sodium retention, activation of the renin angiotensin aldosterone system, and vascular dysfunction. Obstructive sleep apnea is another common but frequently underdiagnosed contributor, with intermittent hypoxia and sympathetic nervous system activation promoting persistent blood pressure elevation. Patients with resistant hypertension should also be evaluated for endocrine disorders, particularly primary aldosteronism, which is increasingly recognized as one of the most common and treatable causes of secondary hypertension. Other important considerations include renovascular disease, pheochromocytoma, Cushing syndrome, thyroid disorders, and rare genetic forms of hypertension where clinically indicated.
The therapeutic landscape for resistant hypertension has evolved substantially in recent years. Mineralocorticoid receptor antagonists, particularly spironolactone, remain the cornerstone of fourth line pharmacologic therapy following optimization of standard antihypertensive regimens. Multiple clinical trials have demonstrated that spironolactone provides superior blood pressure reduction compared with alternative add on therapies in appropriately selected patients. Nevertheless, careful monitoring for hyperkalemia and declining renal function is required, particularly in individuals with chronic kidney disease or concomitant use of renin angiotensin system inhibitors.
Beyond spironolactone, several emerging therapeutic strategies are expanding treatment options for patients with resistant hypertension. Endothelin receptor antagonists are being investigated for their ability to reduce vascular resistance by blocking the potent vasoconstrictive effects of endothelin. Aldosterone synthase inhibitors represent another promising class that directly suppresses aldosterone production while potentially avoiding some limitations associated with mineralocorticoid receptor blockade. In addition, catheter based renal denervation has reemerged as a viable interventional therapy following improvements in procedural techniques and supportive evidence from contemporary randomized clinical trials demonstrating modest but sustained reductions in blood pressure among carefully selected patients.
Advances in the understanding of endocrine mechanisms underlying hypertension have also influenced contemporary screening recommendations. The 2025 Endocrine Society guideline on primary aldosteronism represents a significant shift in clinical practice by conditionally recommending aldosterone renin ratio screening for all adults with hypertension rather than restricting testing to traditionally defined high risk groups. This recommendation reflects growing evidence that primary aldosteronism is substantially more prevalent than previously recognized and often remains undiagnosed across the spectrum of hypertension severity. Early identification is particularly important because targeted treatment with mineralocorticoid receptor antagonists or adrenalectomy in appropriate patients can significantly improve blood pressure control and reduce cardiovascular and renal complications.
The guideline also recognizes that implementation of universal screening may vary across healthcare systems. Availability of laboratory resources, local expertise in interpreting aldosterone renin testing, access to confirmatory testing, and healthcare infrastructure may influence how broadly these recommendations can be adopted. Consequently, clinicians must balance evidence based recommendations with practical considerations specific to their clinical environment while maintaining a high index of suspicion for secondary hypertension.
Overall, resistant hypertension should no longer be viewed simply as uncontrolled blood pressure requiring additional medications. Instead, it should be approached as a multifactorial diagnostic syndrome that demands careful evaluation of measurement accuracy, medication adherence, lifestyle influences, pharmacologic contributors, and secondary causes before confirming true treatment resistance. This comprehensive approach allows clinicians to individualize therapy, identify reversible causes, and incorporate emerging pharmacologic and device based interventions when appropriate. As advances in hypertension research continue to reshape clinical practice, integrating systematic diagnostic evaluation with evidence based treatment strategies offers the greatest opportunity to improve cardiovascular outcomes in patients with resistant hypertension.
Why Resistant Hypertension Matters Now
The current clinical challenge is not simply that some patients require more medication. Resistant hypertension often identifies a high-risk phenotype in which one or more mechanisms contributing to blood pressure elevation may be modifiable.
The 2024 European Society of Cardiology guideline defines resistant hypertension as office systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at least 90 mm Hg despite maximally tolerated doses of a diuretic, a renin-angiotensin system blocker, and a calcium-channel blocker. The diagnosis requires confirmation with home or ambulatory blood pressure monitoring and exclusion of pseudo-resistance.
The 2025 ACC/AHA hypertension guideline also emphasizes resistant hypertension, secondary hypertension, primary aldosteronism, home blood pressure monitoring, team-based care, and renal denervation. It recommends primary aldosteronism screening in patients with resistant hypertension regardless of whether hypokalemia is present.
This point is clinically important because normokalemia does not exclude autonomous aldosterone secretion.
Confirm True Resistance Before Escalating Therapy
The first step in resistant hypertension is confirmation, not automatic escalation.
Pseudo-resistance remains common and may reflect:
- Inaccurate blood pressure measurement
- Inappropriate cuff size
- White-coat effect
- Underdosing
- Therapeutic inertia
- Poor adherence
- An inadequate diuretic strategy
- Inappropriate medication combinations
The 2018 American Heart Association scientific statement emphasized that resistant hypertension requires exclusion of the white-coat effect and assessment of adherence before the diagnosis is accepted.
A practical confirmation process includes standardized office measurement, structured home or ambulatory blood pressure monitoring when feasible, review of refill history and medication-taking barriers, and reassessment of the treatment regimen.
For most patients, foundational therapy should include a long-acting dihydropyridine calcium-channel blocker, a renin-angiotensin system blocker, and an appropriately selected diuretic. In advanced chronic kidney disease, effective volume management may require a loop diuretic rather than a thiazide or thiazide-like diuretic.
Aldosterone and Renin: Useful Physiology, Not a Stand-Alone Diagnosis
Aldosterone-renin profiling may help identify whether the biochemical pattern suggests volume expansion, renin suppression, inappropriate aldosterone secretion, renin-mediated physiology, or medication interference.
Low renin in resistant hypertension may reflect sodium retention, low-renin hypertension, primary aldosteronism, chronic kidney disease physiology, age, race-associated physiologic variation, or medication effects. High renin may reflect diuretic exposure, renin-angiotensin system blockade, renovascular disease, nonadherence patterns, or secondary aldosteronism.
The key caution is that renin profiling is not equivalent to diagnosing primary aldosteronism.
The Endocrine Society recommends screening with paired serum or plasma aldosterone and renin measurements, interpreted together with the aldosterone-renin ratio and serum potassium. Testing should account for:
- Timing and posture
- Sodium intake
- Potassium status
- Interfering medications
- Assay-specific thresholds
- Pretest probability
- Kidney function
- The clinical safety of medication withdrawal
Hypokalemia can suppress aldosterone secretion and produce a falsely reassuring result. Chronic kidney disease and antihypertensive medications can also alter aldosterone, renin, and the aldosterone-renin ratio.
When initial results are negative despite substantial clinical suspicion, clinicians should correct hypokalemia when present and consider repeat testing under safer or more interpretable conditions.
Table 1. Aldosterone-Renin Patterns in Resistant Hypertension
| Pattern | Possible interpretation and practical response |
| Low renin with inappropriately elevated aldosterone | Raises suspicion for primary aldosteronism. Apply assay-specific criteria, correct hypokalemia, review interfering medications, and follow an appropriate primary aldosteronism pathway. |
| Low renin with low or low-normal aldosterone | May reflect sodium-volume excess, chronic kidney disease, low-renin hypertension, aging, medication effects, or other physiology. Review sodium intake, diuretic adequacy, NSAID exposure, and licorice use. Do not diagnose primary aldosteronism without adequate aldosterone support. |
| High renin with high aldosterone | May reflect diuretic or renin-angiotensin system blocker effects, renovascular disease, secondary aldosteronism, or adherence patterns. Interpret in the context of medications and the clinical phenotype. |
| Suppressed renin during treatment for primary aldosteronism | May suggest inadequate mineralocorticoid receptor blockade when blood pressure remains uncontrolled. Consider cautious treatment intensification when clinically appropriate. Renin-targeted dosing is not a validated universal algorithm. |
Primary Aldosteronism Is Now a Routine Consideration
Primary aldosteronism is one of the most actionable secondary causes of hypertension. Disease-specific treatment may include mineralocorticoid receptor antagonism or, in selected patients with lateralizing unilateral disease, adrenalectomy after appropriate subtype evaluation.
The 2025 Endocrine Society guideline suggests primary aldosteronism-specific therapy rather than nonspecific antihypertensive treatment alone. In surgical candidates who desire adrenalectomy, adrenal imaging and adrenal venous sampling are generally used to evaluate disease laterality, although limited exceptions may apply.
Medical therapy is appropriate for patients with bilateral disease, patients who are not surgical candidates, those who do not desire surgery, and patients who are unwilling or unable to complete subtype evaluation.
Primary aldosteronism should not be reserved for the classic patient with severe hypertension and hypokalemia. Resistant hypertension, adrenal incidentaloma, spontaneous or diuretic-induced hypokalemia, early-onset hypertension, disproportionate target-organ injury, and a family history of early-onset hypertension or stroke increase clinical suspicion.
Broad screening should still be implemented thoughtfully. Interpretation must account for local laboratory thresholds, medication interference, resource availability, access to confirmatory testing, and specialist referral pathways.
Secondary Workups Should Be Structured, Not Indiscriminate
Renewed attention to secondary hypertension should not lead to indiscriminate testing. It should prompt a disciplined review of common, clinically important, and potentially actionable contributors.
These include:
- Primary aldosteronism
- Chronic kidney disease
- Renovascular disease
- Obstructive sleep apnea
- Drug- or substance-induced hypertension
- Sodium-volume excess
Medication and substance review may be as important as endocrine testing. Potential contributors include nonsteroidal anti-inflammatory drugs, sympathomimetics, prescription and nonprescription stimulants, glucocorticoids, calcineurin inhibitors, erythropoiesis-stimulating agents, estrogen-containing contraceptives, testosterone or anabolic agents, licorice, excess alcohol, and high sodium intake.
The depth of the workup should be guided by the patient’s phenotype, severity, age at onset, progression, kidney function, electrolyte abnormalities, vascular findings, and evidence of target-organ damage.
Table 2. Practical Evaluation of Apparent Resistant Hypertension
| Clinical question | Practical implication |
| Is blood pressure truly uncontrolled? | Review measurement technique and cuff size. Confirm with validated home monitoring or ambulatory blood pressure monitoring when feasible. |
| Is the regimen adequate? | Review doses, medication duration, drug combinations, and diuretic selection. Optimize foundational therapy. |
| Is adherence plausible? | Review access, cost, adverse effects, refill patterns, regimen complexity, and medication-taking barriers without blame. |
| Is sodium-volume excess present? | Review sodium intake, edema, kidney function, diuretic response, NSAID exposure, and low-renin physiology. |
| Is primary aldosteronism plausible? | Measure aldosterone, renin, aldosterone-renin ratio, and potassium using an interpretable testing strategy. |
| Is another secondary cause plausible? | Use phenotype-directed testing for kidney disease, renovascular disease, sleep apnea, medication effects, and other suspected causes. |
Optimizing the Foundation Still Comes First
Before adding newer therapies, clinicians should optimize the treatment regimen and address the sodium-volume axis.
Single-pill combinations, once-daily administration when appropriate, and careful diuretic selection may improve adherence and blood pressure control. Resistant hypertension frequently reflects salt retention or volume expansion, particularly in chronic kidney disease.
Hydrochlorothiazide may be replaced by a longer-acting thiazide-like diuretic in selected patients. When estimated glomerular filtration rate falls below approximately 30 mL/min/1.73 m², a loop diuretic is generally required for adequate diuresis, although individual response and contemporary chronic kidney disease evidence should inform the final choice.
Spironolactone Remains the Fourth-Line Reference Standard
Spironolactone remains the benchmark fourth-line therapy for many patients with confirmed resistant hypertension.
In PATHWAY-2, spironolactone lowered home systolic blood pressure more effectively than placebo, bisoprolol, or doxazosin as add-on therapy. Mechanistic substudies supported the concept that sodium retention and low-renin physiology contribute to many cases of resistant hypertension.
These findings do not mean that every patient has primary aldosteronism or that comparative drug efficacy alone proves a single aldosterone-driven mechanism.
The 2024 ESC guidance proposes spironolactone 25 to 50 mg once daily as a preferred add-on option. It advises against use when estimated glomerular filtration rate is below 30 mL/min/1.73 m² or serum potassium is above 4.5 mmol/L and recommends close monitoring of kidney function and potassium after initiation and during continued therapy.
Safe selection also requires consideration of:
- Baseline and previous hyperkalemia
- Concomitant renin-angiotensin system inhibitors
- Potassium supplements and potassium-containing salt substitutes
- Other medications that increase potassium
- Addison disease
- Concurrent eplerenone therapy
- Renal function
- Monitoring capacity
- Pregnancy or pregnancy potential
Current labeling advises avoiding spironolactone during pregnancy because its antiandrogenic properties may pose a potential risk to a male fetus.
Gynecomastia and other endocrine adverse effects may limit treatment. Eplerenone may be considered when antiandrogenic intolerance is the principal problem, but it shares clinically important hyperkalemia and renal-function limitations and is affected by CYP3A interactions. It should not be assumed to be safe when hyperkalemia or significant kidney dysfunction makes spironolactone unsuitable.
Amiloride as a Selected Alternative
Amiloride may be considered in selected patients when spironolactone intolerance is the limiting factor.
A 2025 randomized clinical trial involving patients with confirmed resistant hypertension found that amiloride was noninferior to spironolactone for reduction in home systolic blood pressure over 12 weeks. This supports amiloride as a short-term blood pressure-lowering alternative in selected patients.
The trial does not establish equivalence for long-term cardiovascular or renal outcomes.
Amiloride is also a potassium-sparing drug. Hyperkalemia and renal function require monitoring, and current U.S. labeling contraindicates use in patients with hyperkalemia, anuria, acute or chronic renal insufficiency, or evidence of diabetic nephropathy.
Amiloride should therefore not be treated as a universal substitute when spironolactone is unsuitable because of hyperkalemia or impaired kidney function.
Newer Pharmacologic Options Require Careful Safety Framing
Aprocitentan
Aprocitentan is a dual endothelin receptor antagonist approved for use with other antihypertensive drugs in adults whose blood pressure is not adequately controlled on other therapies.
In the PRECISION trial, participants had resistant hypertension despite standardized background treatment with three antihypertensive drugs, including a diuretic. Aprocitentan reduced office and ambulatory systolic blood pressure more than placebo. Edema and fluid retention were among the most frequent adverse effects.
The approved dose of TRYVIO is 12.5 mg once daily.
Current U.S. labeling includes:
- A boxed warning for embryo-fetal toxicity
- Contraindication during pregnancy
- Contraindication in patients with hypersensitivity
- Pregnancy testing before initiation in patients who can become pregnant
- Effective contraception before treatment, during treatment, and for one month after discontinuation
- Warnings for hepatotoxicity
- Fluid retention
- Hemoglobin reduction
- Decreased sperm counts
- Advice against breastfeeding during treatment
Serum aminotransferases and bilirubin should be measured before treatment and periodically during treatment according to the prescribing information.
The label states that controlled trials have not demonstrated cardiovascular event reduction specifically with aprocitentan.
Baxdrostat
Baxdrostat is an aldosterone synthase inhibitor that reduces aldosterone production rather than blocking the mineralocorticoid receptor.
BAXFENDY received initial U.S. approval in 2026. It is indicated in combination with other antihypertensive drugs for adults whose blood pressure is not adequately controlled on other agents. The indication does not require documented primary aldosteronism, an elevated aldosterone-renin ratio, suppressed renin, or another biomarker-defined phenotype.
The recommended dose is 2 mg once daily. The recommended dose is 1 mg once daily for patients at increased risk of hyperkalemia or hyponatremia.
The phase 3 BaxHTN trial enrolled adults with uncontrolled or resistant hypertension and demonstrated greater 12-week seated systolic blood pressure reductions with baxdrostat 1 mg and 2 mg than with placebo.
Current labeling identifies hyperkalemia and hyponatremia as principal warnings and precautions. Serum potassium and sodium should be assessed before initiation and monitored periodically, with more frequent monitoring in higher-risk patients.
Other adverse reactions reported more frequently than with placebo included hypotension, dizziness, and muscle spasms. A mean reduction in estimated glomerular filtration rate was observed during clinical trials. The mean value increased after discontinuation, suggesting a hemodynamic component.
Drugs that increase serum potassium require additional monitoring. Strong or moderate CYP3A inducers may reduce baxdrostat exposure and treatment effect.
There are no controlled trials demonstrating cardiovascular event reduction specifically with BAXFENDY.
Table 3. Add-On Options After True Resistance Is Confirmed
| Option | Potential role and principal limitation |
| Spironolactone | Preferred fourth-line reference option for many patients when kidney function, potassium, drug interactions, pregnancy considerations, and monitoring capacity permit. |
| Eplerenone | May be considered when spironolactone causes antiandrogenic adverse effects. Shares hyperkalemia and renal limitations and has clinically important CYP3A interactions. |
| Amiloride | Short-term trial evidence supports blood pressure-lowering noninferiority to spironolactone in selected patients. Hyperkalemia and renal contraindications limit use. Long-term outcomes evidence is limited. |
| Aprocitentan | Approved for adults not adequately controlled on other drugs. Requires pregnancy precautions, liver testing, and monitoring for fluid retention and hemoglobin reduction. No drug-specific cardiovascular outcomes trial. |
| Baxdrostat | Approved for adults not adequately controlled on other agents. Does not require a biomarker-selected phenotype. Monitor potassium, sodium, kidney function, interacting medications, and treatment response. No drug-specific cardiovascular outcomes trial. |
| Renal denervation | Device-based adjunct for selected patients after confirmation of uncontrolled hypertension, medication optimization, and secondary evaluation. Requires appropriate anatomy, expertise, and system-specific patient selection. |
Renal Denervation Is an Adjunct, Not an Escape From Workup
Renal denervation has re-entered clinical practice after earlier uncertainty and newer sham-controlled evidence.
The FDA approved the Paradise Ultrasound Renal Denervation System and the Symplicity Spyral Renal Denervation System in 2023. Both are indicated to reduce blood pressure as adjunctive treatment in patients whose hypertension is not adequately controlled with lifestyle measures and antihypertensive medications.
Device indications, warnings, vascular-anatomy requirements, and exclusions differ by system. Clinicians should review the current labeling for the specific device.
For the Paradise system, labeled exclusions include:
- Pregnancy
- Renal arteries outside the labeled diameter range
- Renal artery fibromuscular dysplasia
- A previously stented renal artery
- Renal artery aneurysm
- Renal artery stenosis greater than 30%
- Abnormal kidney tumors or secreting adrenal tumors
- Iliac or femoral artery stenosis that prevents catheter insertion
The 2024 American Heart Association scientific statement describes renal denervation as a promising treatment option while emphasizing unresolved questions regarding patient selection, durability, clinical outcomes, access, and implementation.
Renal denervation should be considered only after pseudo-resistance, adherence barriers, secondary causes, and medication optimization have been addressed. It is an adjunctive treatment, not a substitute for diagnostic evaluation.
Practical Approach for Clinicians
A practical workflow begins with confirmation.
Reassess office technique, verify the accuracy of home blood pressure devices when possible, obtain ambulatory or structured home measurements, and review adherence without blame. Simplify the regimen where feasible, reduce pill burden, and ask directly about cost, adverse effects, missed doses, and competing priorities.
The second step is phenotyping. Basic evaluation should generally include serum electrolytes, creatinine with estimated glomerular filtration rate, urine albumin-creatinine ratio, and review of sodium intake, sleep apnea symptoms, kidney disease, pressor medications or substances, alcohol intake, and target-organ damage.
Aldosterone, renin, aldosterone-renin ratio, and potassium should be obtained when primary aldosteronism is being evaluated. The Endocrine Society now conditionally suggests screening all adults with hypertension, while current cardiovascular guidance supports a particularly low threshold in resistant hypertension.
The third step is treatment selection.
When kidney function, potassium, interacting medications, reproductive considerations, and monitoring capacity permit, spironolactone remains the usual fourth-line reference standard.
When spironolactone is not tolerated because of antiandrogenic effects, eplerenone may be considered if its own safety requirements are met. Amiloride may be considered in selected patients but shares important potassium and renal limitations.
When blood pressure remains uncontrolled after optimized foundational therapy and a structured secondary workup, aprocitentan, baxdrostat, renal denervation, or referral to a hypertension specialist may be considered according to comorbidities, renal function, electrolyte status, reproductive potential, monitoring feasibility, medication access, device availability, and patient preference.
This approach is consistent with current guideline principles for confirming resistance, optimizing foundational treatment, and evaluating secondary causes. Selection of newer agents must additionally follow current FDA labeling and emerging clinical evidence.
Limitations of the Evidence
Much of the resistant-hypertension evidence relies on blood pressure endpoints rather than therapy-specific cardiovascular outcomes.
Across antihypertensive therapy broadly, blood pressure lowering is established to reduce cardiovascular risk. That body of evidence does not establish that every new add-on agent has direct, drug-specific evidence for preventing myocardial infarction, stroke, heart failure, kidney failure, or cardiovascular death.
Current FDA labeling for both aprocitentan and baxdrostat explicitly notes the absence of controlled trials demonstrating cardiovascular event reduction with the individual drug.
Renin-guided treatment is also not fully settled. The 2025 Endocrine Society guideline suggests increasing primary aldosteronism-specific medical therapy to raise renin when blood pressure remains uncontrolled and renin remains suppressed.
The guideline notes uncertainty about titrating therapy solely to raise renin when blood pressure is already controlled. Physiology-guided care should therefore not be presented as a validated precision-medicine algorithm for all patients with resistant hypertension.
Drug and device trials also differ in definitions of resistant hypertension, background therapy, adherence assessment, blood pressure measurement methods, duration, outcome selection, and patient population. Results should not automatically be generalized beyond the populations and treatment pathways studied.
Resistant hypertension remains one of the most challenging conditions in cardiovascular medicine, affecting a substantial proportion of patients despite the widespread availability of effective antihypertensive therapies. Traditionally viewed as persistent elevation of blood pressure despite treatment with multiple medications, resistant hypertension is now increasingly recognized as a heterogeneous clinical syndrome rather than a single disease entity. Contemporary evidence demonstrates that successful management requires an individualized, physiology based approach that extends well beyond simply adding another antihypertensive agent. The optimal therapeutic strategy depends on a comprehensive understanding of the mechanisms driving elevated blood pressure in each patient, including medication adherence, renal function, sodium balance, aldosterone excess, renin activity, obstructive sleep apnea, vascular pathology, reproductive considerations, medication tolerability, and the patient’s capacity for ongoing monitoring and follow up.
This shift toward personalized management reflects advances in hypertension research that have improved understanding of the complex biological pathways underlying treatment resistance. While some patients may ultimately benefit from novel pharmacologic agents or device based therapies such as renal denervation, many achieve meaningful blood pressure control through careful evaluation and correction of reversible contributors. Consequently, modern management emphasizes precise phenotyping of resistant hypertension before therapeutic escalation.
An important development in recent years has been the renewed emphasis on evaluating secondary causes of hypertension. Growing evidence indicates that a considerable proportion of patients initially classified as having resistant hypertension actually have identifiable and potentially treatable underlying conditions. Primary aldosteronism, chronic kidney disease, renovascular hypertension, obstructive sleep apnea, endocrine disorders, medication induced hypertension, and excessive dietary sodium intake are among the most common contributors. These conditions frequently coexist, creating overlapping pathophysiologic mechanisms that complicate diagnosis and treatment. In many cases, no single dominant mechanism explains persistent hypertension, requiring clinicians to address multiple contributing factors simultaneously.
Before establishing a diagnosis of true resistant hypertension, clinicians must first exclude pseudoresistance. Apparent treatment failure may result from inaccurate blood pressure measurement techniques, the white coat effect, inadequate medication dosing, poor adherence, suboptimal drug combinations, or therapeutic inertia. Confirmation with standardized office measurements, home blood pressure monitoring, or ambulatory blood pressure monitoring is therefore essential. Equally important is a careful review of medication adherence through patient interviews, pharmacy refill records, pill counts, or biochemical testing when appropriate. Failure to identify pseudoresistance may expose patients to unnecessary investigations and potentially harmful treatment intensification.
Once true resistance has been confirmed, evaluation should focus on identifying physiologic mechanisms that can guide individualized therapy. Assessment of extracellular volume status, renal function, serum electrolytes, plasma aldosterone concentration, plasma renin activity or direct renin concentration, and urinary sodium excretion may provide valuable insights into the dominant drivers of hypertension. Screening for primary aldosteronism has become particularly important because this condition is increasingly recognized as one of the most common and underdiagnosed causes of resistant hypertension. Similarly, assessment for obstructive sleep apnea should be considered in patients with obesity, excessive daytime sleepiness, resistant nocturnal hypertension, or suggestive clinical features.
Optimization of foundational therapy remains the cornerstone of management. Lifestyle interventions including dietary sodium restriction, weight reduction, regular physical activity, moderation of alcohol intake, smoking cessation, and treatment of obstructive sleep apnea should accompany pharmacologic therapy in every patient. Medication regimens should prioritize evidence based combinations at maximally tolerated doses, with careful attention to renal function, electrolyte balance, and drug interactions. Mineralocorticoid receptor antagonists continue to play a central role in many patients with resistant hypertension, particularly when aldosterone excess is suspected, although careful monitoring for hyperkalemia and declining renal function is essential.
Patient safety remains a critical consideration throughout treatment. Advanced age, chronic kidney disease, diabetes mellitus, heart failure, pregnancy potential, and polypharmacy may significantly influence therapeutic decisions. Women of reproductive age require careful selection of antihypertensive medications because several commonly used agents, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are contraindicated during pregnancy due to fetal toxicity. Likewise, declining kidney function may necessitate medication adjustments and closer laboratory surveillance. Individualized monitoring strategies should therefore be developed according to each patient’s clinical profile, treatment regimen, and risk of adverse events.
When blood pressure remains uncontrolled despite optimized medical therapy and correction of secondary contributors, additional treatment options may be considered. These include emerging pharmacologic therapies, referral to hypertension specialists, and, in carefully selected patients, device based interventions such as catheter based renal denervation. Recent clinical trials have demonstrated modest but sustained reductions in blood pressure following renal denervation in selected populations, although patient selection, procedural expertise, and long term outcome data continue to evolve. Decisions regarding advanced therapies should be made within the context of multidisciplinary care and shared decision making.
Ultimately, the clinician’s role extends beyond prescribing antihypertensive medications. Effective management requires confirmation of true treatment resistance, systematic evaluation for secondary causes, identification of the most likely physiologic mechanisms contributing to persistent hypertension, optimization of lifestyle and pharmacologic therapy, vigilant safety monitoring, and thoughtful escalation of treatment only after fundamental diagnostic and therapeutic principles have been fully addressed. This comprehensive approach maximizes the likelihood of achieving durable blood pressure control while minimizing unnecessary interventions and treatment related complications.
Clinical Update Disclaimer
This review reflects major clinical guidelines, landmark clinical trials, United States Food and Drug Administration device information, and United States prescribing information available through July 25, 2026. Because the field of hypertension management continues to evolve, recommendations regarding resistant hypertension, primary aldosteronism, antihypertensive drug indications, boxed warnings, laboratory monitoring, renal denervation, and other device based therapies may change as new evidence becomes available.
Before applying the recommendations discussed in this review, clinicians should consult the most current guidance from the American College of Cardiology, the American Heart Association, the European Society of Cardiology, the Endocrine Society, the United States Food and Drug Administration, DailyMed, relevant institutional protocols, and the latest peer reviewed clinical literature. This article is intended for educational purposes and should not be interpreted as establishing a standard of care. Clinical decision making should always be individualized based on patient specific factors, laboratory findings, specialist consultation when appropriate, shared decision making, and the independent professional judgment of the treating clinician.
References
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., Williams, T. A., Yang, J., Young, W. F., Zennaro, M. C., & Brito, J. P. (2025). Primary aldosteronism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 110(9), 2453-2495. https://doi.org/10.1210/clinem/dgaf284
PMID: 40658480
American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2025). 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2025.05.007
PMID: 40811497
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., Lackland, D. T., Laffer, C. L., Newton-Cheh, C., Smith, S. M., Taler, S. J., Textor, S. C., Turan, T. N., & White, W. B. (2018). Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension, 72(5), e53-e90. https://doi.org/10.1161/HYP.0000000000000084
PMID: 30354828
Cluett, J. L., Blazek, O., Brown, A. L., East, C., Ferdinand, K. C., Fisher, N. D. L., Ford, C. D., Griffin, K. A., Mena-Hurtado, C. I., Sarathy, H., Vongpatanasin, W., & Townsend, R. R. (2024). Renal denervation for the treatment of hypertension: A scientific statement from the American Heart Association. Hypertension, 81(10), e135-e148. https://doi.org/10.1161/HYP.0000000000000240
PMID: 39101202
DailyMed. (2026). ALDACTONE (spironolactone) tablets prescribing information. National Library of Medicine. Retrieved July 25, 2026, from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc
DailyMed. (2026). Amiloride hydrochloride tablets prescribing information. National Library of Medicine. Retrieved July 25, 2026, from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=18d551a9-ffc7-4b14-adbd-92d84aa8e966&type=display
DailyMed. (2026). BAXFENDY (baxdrostat) tablets prescribing information. National Library of Medicine. Retrieved July 25, 2026, from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1fc1ee7-facc-4099-b3db-a4c1daeaa4be&type=display
DailyMed. (2026). Eplerenone tablets prescribing information. National Library of Medicine. Retrieved July 25, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed
DailyMed. (2026). TRYVIO (aprocitentan) tablets prescribing information. National Library of Medicine. Retrieved July 25, 2026, from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dfe7a2ee-612c-4aba-834a-d68e6b59a0a6
Flack, J. M., Azizi, M., Brown, J. M., Dwyer, J. P., Fronczek, J., Jones, E. S. W., Olsson, D. S., Perl, S., Shibata, H., Wang, J. G., Wilderäng, U., Wittes, J., & Williams, B. (2025). Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. The New England Journal of Medicine, 393(14), 1363-1374. https://doi.org/10.1056/NEJMoa2507109
PMID: 40888730
Freeman, M. W., Halvorsen, Y. D., Marshall, W., Pater, M., Isaacsohn, J., Pearce, C., Murphy, B., Alp, N., Srivastava, A., Bhatt, D. L., & Brown, M. J. (2023). Phase 2 trial of baxdrostat for treatment-resistant hypertension. The New England Journal of Medicine, 388, 395-405. https://doi.org/10.1056/NEJMoa2213169
PMID: 36342143
Lee, C. J., Ihm, S. H., Shin, D. H., Jeong, J. O., Kim, J. H., Chun, K. H., Ryu, J., Lee, H. Y., Choi, S., Lee, E. M., Choi, J. H., Kim, K. I., Shin, J., Pyun, W. B., Kim, D. H., Park, S., & Williams, B. (2025). Spironolactone vs amiloride for resistant hypertension: A randomized clinical trial. JAMA, 333(23), 2073-2082. https://doi.org/10.1001/jama.2025.5129
PMID: 40366680
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., Hanssen, H., Harris, J., Lauder, L., McManus, R. J., Molloy, G. J., Rahimi, K., Regitz-Zagrosek, V., Rossi, G. P., Sandset, E. C., … Williams, B. (2024). 2024 ESC guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, 45(38), 3912-4018. https://doi.org/10.1093/eurheartj/ehae178
PMID: 39210715
Schlaich, M. P., Bellet, M., Weber, M. A., Danaietash, P., Bakris, G. L., Flack, J. M., Dreier, R. F., Sassi-Sayadi, M., Haskell, L. P., Narkiewicz, K., Wang, J. G., & PRECISION Investigators. (2022). Dual endothelin antagonist aprocitentan for resistant hypertension: A multicentre, blinded, randomised, parallel-group, phase 3 trial. The Lancet, 400(10367), 1927-1937. https://doi.org/10.1016/S0140-6736(22)02034-7
PMID: 36356632
U.S. Food and Drug Administration. (2023). Paradise Ultrasound Renal Denervation System: P220023. Retrieved July 25, 2026, from https://www.fda.gov/medical-devices/recently-approved-devices/paradise-ultrasound-renal-denervation-system-p220023
U.S. Food and Drug Administration. (2023). Symplicity Spyral Renal Denervation System: P220026. Retrieved July 25, 2026, from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., Mackenzie, I. S., Padmanabhan, S., Brown, M. J., & British Hypertension Society’s PATHWAY Studies Group. (2015). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension: PATHWAY-2. The Lancet, 386(10008), 2059-2068. https://doi.org/10.1016/S0140-6736(15)00257-3
PMID: 26414968
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., Mackenzie, I. S., Padmanabhan, S., Brown, M. J., & British Hypertension Society’s PATHWAY Studies Group. (2018). Endocrine and haemodynamic changes in resistant hypertension and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies. The Lancet Diabetes & Endocrinology, 6(6), 464-475. https://doi.org/10.1016/S2213-8587(18)30071-8
PMID: 29655877
Recent Articles
Integrative Perspectives on Cognition, Emotion, and Digital Behavior
Sleep-related:
Longevity/Nutrition & Diet:
Philosophical / Happiness / Social:
Other:
Modern Mind Unveiled
Developed under the direction of David McAuley, Pharm.D., this collection explores what it means to think, feel, and connect in the modern world. Drawing upon decades of clinical experience and digital innovation, Dr. McAuley and the GlobalRPh initiative translate complex scientific ideas into clear, usable insights for clinicians, educators, and students.
The series investigates essential themes–cognitive bias, emotional regulation, digital attention, and meaning-making—revealing how the modern mind adapts to information overload, uncertainty, and constant stimulation.
At its core, the project reflects GlobalRPh’s commitment to advancing evidence-based medical education and clinical decision support. Yet it also moves beyond pharmacotherapy, examining the psychological and behavioral dimensions that shape how healthcare professionals think, learn, and lead.
Through a synthesis of empirical research and philosophical reflection, Modern Mind Unveiled deepens our understanding of both the strengths and vulnerabilities of the human mind. It invites readers to see medicine not merely as a science of intervention, but as a discipline of perception, empathy, and awareness–an approach essential for thoughtful practice in the 21st century.
The Six Core Themes
I. Human Behavior and Cognitive Patterns
Examining the often-unconscious mechanisms that guide human choice-how we navigate uncertainty, balance logic with intuition, and adapt through seemingly irrational behavior.
II. Emotion, Relationships, and Social Dynamics
Investigating the structure of empathy, the psychology of belonging, and the influence of abundance and selectivity on modern social connection.
III. Technology, Media, and the Digital Mind
Analyzing how digital environments reshape cognition, attention, and identity- exploring ideas such as gamification, information overload, and cognitive “nutrition” in online spaces.
IV. Cognitive Bias, Memory, and Decision Architecture
Exploring how memory, prediction, and self-awareness interact in decision-making, and how external systems increasingly serve as extensions of thought.
V. Habits, Health, and Psychological Resilience
Understanding how habits sustain or erode well-being-considering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts.
VI. Philosophy, Meaning, and the Self
Reflecting on continuity of identity, the pursuit of coherence, and the construction of meaning amid existential and informational noise.
Keywords
Cognitive Science • Behavioral Psychology • Digital Media • Emotional Regulation • Attention • Decision-Making • Empathy • Memory • Bias • Mental Health • Technology and Identity • Human Behavior • Meaning-Making • Social Connection • Modern Mind
Video Section
